Introduction
For over 40 years, GCs have been used to successfully treat myeloma patients, and they have continued to be included as part of combination therapies for the last 20 years, highlighting the important contribution of this drug to the treatment of myeloma [Cavo et al., 2011 ; Rajkumar et al., 2002 ] . In addition, expression of the glucocorticoid receptor (GR) in myeloma patients correlates with better overall patient survival, underscoring the importance Nuclear Receptor Signaling | www.nrsignaling.org NRS | 2015 | Vol. 13 | doi:10.1621 of this signaling pathway in myeloma clinical outcome [Heuck et al., 2012 ] . Despite the long-term use of this drug, the mechanism of action is largely unknown. With the growing trend of combining therapeutics that target different pathways, it becomes imperative to understand the primary downstream targets for GCs to enable efficacious use of this drug. In addition, understanding the GC targets that are required for cell death will provide the basis for the development of novel therapeutics that induce cell death in the face of GC resistance caused by loss of the GR.
GCs mediate their biological effects through the GR. We and others [Moalli et al., 1992 ] have demonstrated that the intact receptor is required for apoptosis, as hematologic cell lines with absent or mutant receptors evade the cytotoxic effects of GCs [Greenstein et al., 2002 ; Kofler, 2000 ] . In canonical GC signaling, ligand binding induces a conformational change in GR, which releases the receptor from its chaperones, and allows translocation to the nucleus, where it then binds to a consensus DNA sequence termed the glucocorticoid response element (GRE).
Interaction of GR with the GRE stimulates binding of nuclear receptor co-regulators, which modulates transcription of target genes. In addition to induction of gene expression, GR also acts to repress transcription. The trans-repressive functions of the GR have been linked to the anti-inflammatory and pro-apoptotic actions of GCs [Zanchi et al., 2010 ] . Proposed mechanisms for repression include GR tethering to and inhibiting growth induction transcription factors through protein-protein interactions or by interactions with growth induction transcription factors at composite GREs [Yamamoto et al., 1998 ]. However, despite extensive gene expression array analyses, specific genes that mediate cell death have not been well defined, perhaps in part because recent data support GCs acting through the GR to impact a complex network of activators [Beato et al., 1995 ; Hollenberg et al., 1985; Martin, 2003; Wilson et al., 2013] .
Initial identification of the glucocorticoid receptor as a hormone-activated transcription factor [Beato et al., 1995; Hollenberg et al., 1985] was the basis of the hypothesis that glucocorticoid-induced cell death involved the activation of specific "death" genes. Several laboratories, including ours, have conducted GC-regulated gene expression analyses in a variety of cell lines of hematologic origin. Over 900 different genes have been reported to be GC-regulated, but only about 70 have appeared in more than one publication [Schmidt et al., 2004] . Due to the difficulties in identifying a single primary deathinducing gene, it has been suggested that multiple cell type-dependent mechanisms may exist. Rather than a single conserved canonical pathway causing GC-induced cell death, a network of GC-induced gene action interacting with other signaling pathways may be triggering cell death [Schmidt et al., 2004] . As an example, we have noted that GILZ (glucocorticoid induced leucine zipper), a protein involved in GCmediated cell death, is synergistically induced by a combination of GC and PI3 kinase pathway inhibition [Grugan et al., 2008] . More recently, systems biology approaches indicate that cellular signaling pathways, such as glucocorticoid signaling, are complex, integrated pathways with primary nodes of interaction leading to complex downstream signaling events [Martin, 2003; Wilson et al., 2013] .
To add further complexity, gene expression array data captures regulation of mRNAs that may be primary targets of GR but also may be targets of effectors downstream of GCs. The location and sequence of specific GR binding regions (GBR) in the genome have been published for other cell types So et al., 2007; Yu et al., 2010a] . To distinguish primary GC targets that are directly regulated by GR from the indirect targets that are impacted downstream in our multiple myeloma model, we employed chromatin immunoprecipitation (ChIP) combined with massively parallel sequencing (Seq). The location of GBRs, by proximity to gene coding regions, will identify potential GC-regulated genes.
Combining the location data of GC-regulated genes and mRNA expression data sets will identify primary target candidates of GC activity So et al., 2007; Yu et al., 2010a] . The ChIP-Seq studies reported here identify potential direct gene targets of GR that could be targeted to overcome GCresistance.
ChIP-Seq studies of GR have recently been published for lung cancer cells [So et al., 2007] , mouse breast cancer cells , mouse pituitary cells , and adipocytes [Yu et al., 2010a] , with some startling results. GR ChIP-Seq data indicates that in each cell type examined, approximately 90% of the GBRs were located more than 5 KB from the transcription start site (TSS) and not proximal to the TSS, as had been assumed in the classical model of hormone action. These data imply that the GBR is not acting as a promoter, as was initially thought, but rather in the capacity of an enhancer which regulates the activities of a distant promoter through looping [Biddie et al., 2010] . Interestingly, DHS mapping and the associated GBRs are radically different between cell types, indicating that active GBRs are cell typespecific, which is dictated by the pre-existing chromatin landscape . These data indicate that ChIP-Seq is critical in the identification of active GBRs in myeloma cells.
In this report we have enriched the population of GRregulated genes that contribute to cell death by building on our previous observations that combine a low dose of PI3 kinase inhibitor with glucocorticoid treatment to enhance cell death in myeloma cell lines [Grugan et al., 2008] . To assess clinical relevance, we interrogated gene expression array data from myeloma patients to identify those genes that are over-expressed in myeloma and down-regulated by our combined drug treatment. To further identify those GC-regulated genes that may be primary targets for GR binding in a myeloma setting, we performed ChIPSeq using a myeloma cell line. We used bioinformatics platforms to combine these data sets to identify candidate genes involved in GC-induced cell death. Gene set enrichment analyses identified signaling pathway enrichment for GC-regulated genes as candidates for GC-induced cell death. Ultimately, selected candidate genes were examined for participation in the cell death mechanism through genetic manipulation and assessing the impact on glucocorticoid sensitivity as proof of principle. In the future, this validated gene set can provide the framework to identify and develop critical components of GC-induced cell death as therapeutic targets.
Materials and Methods

Cell culture
MM.1S and MM.1RL cell lines were previously established from a myeloma patient who had been treated with glucocorticoids and become resistant to that treatment. MM.1S cells were sub-cloned from the initial patient isolate through dilution cloning and are sensitive to glucocorticoids, as measured by the induction of cell death [Goldman-Leikin et al., 1980] . MM.1RL cells were isolated through step-wise incubation with increasing concentrations of glucocorticoids and are resistant to the glucocorticoidinduced cell death [Moalli et al., 1992] . MM.1RL cells do not express the glucocorticoid receptor, while MM.1S cells express the glucocorticoid receptor at levels comparable to normal B cells. Cells are cultured as previously described [Tessel et al., 2011] in RPMI-1640 supplemented with 10% fetal bovine serum, 2 mm glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, 2.5 µg/mL fungizone and 0.5 µg/mL plasmocin (InvivoGen) and maintained in a 370 C incubator with 5% CO2.
Cell death assays
Annexin/DAPI staining was performed according to manufacturer directions (BD Biosciences,). Stained cells were analyzed with the LSR Fortessa flow cytometer (BD Biosciences). A total of 20,000 events were collected for experiments. The data were analyzed using FlowJo software (Tree Star).
Immunoblotting: Immunoblotting was performed as described previously [Tessel et al., 2011] . The antibodies used were BCL-XL (Abcam, ab2568), RRM2 (Santa Cruz, E-16 sc-10846), β-actin (Cell Signaling, 8H10D10) and α-tubulin (Cell Signaling, DM1A #3873S).
Quantitative real-time PCR (qRT-PCR)
Reverse transcription polymerase chain reaction (RT-PCR) was performed as previously described [Rovedo et al., 2011] with the following modifications. Total RNA was extracted from cells using RNeasy Kit (Qiagen) according to manufacturer instructions.
Complementary DNA was synthesized from 1µg of RNA using SuperScript Vilo cDNA Synthesis Kit (Invitrogen). qRT-PCR was performed using Taqman gene expression assays (BCL2L1, RRM2, and GILZ) according to manufacturer protocols (Applied Biosystems, Grand Island, NY) in an ABI 7900 Fast instrument. RNA expression was normalized to three independent control genes (YWHAZ, EIF4A2 and RPL13A; Primer Design, Southampton, UK) using the geNorm normalization algorithm (http://medgen.ugent.be/~jvdesomp/genorm/). Each assay was run in triplicate from biologic triplicates.
Gene expression microarray
Total RNA was extracted using Trizol (Life Technologies) and purified with the RNeasy Mini Kit (Qiagen) following manufacturer instructions. RNA was reverse transcribed and the microarray hybridization was performed using the Illumina Gene Expression Sentrix BeadChip HumanHT-12_V4 (Illumina) at the Genomics Core, Northwestern University. Microarray scanned images were imported to Illumina® GenomeStudio for data quality control and the transcriptome profile data was quantilenormalized by the Bioconductor lumi package [Du et al., 2008] . Significant gene expression changes were determined using the t-test (p<0.05) and fold change exceeding 1.25. For hierarchical clustering, gene expression was transformed to z-scores, with respect to the control values, using the R statistical system. A Multiple Myeloma patient gene signature was generated from a publicly-available gene set, GSE6691 [Gutierrez et al., 2007] . In that study, the myeloma patients are newly-diagnosed and untreated. Significant gene expression changes were determined using the t-test (p<0.05) and fold change exceeding 1.25. Comparison with transcriptomic response of MM cells to treatment with GC, PI3K inhibitor, and combination treatment was performed using the R statistical system, as previously described by our group [Bliss-Moreau et al., 2015] ; similar to the analysis strategy used in our prior publication, we did not apply multiple hypothesis testing corrections for the primary gene expression analysis, thereby enabling the integrative analysis to yield a rich set of biologically-interesting targets.
ChIP-Seq
Chromatin immunoprecipitation was performed as described previously [Yu et al., 2010b] , with the following modifications. MM.1S and MM.1RL cells were treated with or without 1 µM dexamethasone (Dex) for 2 h prior to cell harvest. Protein crosslinking to chromatin was achieved through incubation with 1% formaldehyde and chromatin isolated as previously described. Chromatin was sheared by ten 12 second cycles of sonication and lysate cleared by incubation with protein-A linked agarose beads. Antibody against GR (Santa Cruz SC-8992X) or nonspecific IgG was added at a concentration of 3 to 5 µg per sample and incubated overnight at 4o C with rotation. Antibody-bound chromatin was concentrated by incubation with Protein A-linked agarose beads. Crosslinking was reversed by incubation with RNase A and protein digested with Proteinase K. DNA was purified by ethanol precipitation and used for library construction.
The libraries were sequenced on a HiSeq 2000 Sequencing System with a single-end 40 cycle run, yielding 17-31 million reads per sample. Sequenced reads were mapped to the human genome (UCSC build hg19/NCBI build 37) using the Burrows-Wheeler Alignment tool (BWA) [Li and Durbin, 2009] . Highresolution genome-wide maps were derived and visualized in the UCSC Genome Browser (http://genome.ucsc.edu/). The model-based analysis of ChIP-Seq data macs2 [Zhang et al., 2008] peak calling package was used to identify enriched regions, using default parameters. Motifs were inferred using the homer [Heinz et al., 2010] and the meme-chip [Machanick and Bailey, 2011] tools. Genes targets of GR were determined by computing the overlap between the ChIP-Seq peaks and the genes using bedtools [Quinlan and Hall, 2010] and the RefSeq gene definition considering 100,000 base-pair windows around each gene.
Parallel sequencing
Chromatin immunoprecipitated DNA was prepared for sequencing following a modified version of the Illumina Genomic DNA protocol and as described previously [Yu et al., 2010b] (above). In brief, sheared DNA fragments undergo end repair by T4 DNA polymerase to fill in 5' overhangs, Klenow polymerase to remove 3' overhangs, and T4PNK to phosphorylate the 5'-OH. For Illumina adapter ligation, a single adenine nucleotide overhang must be added to the polished DNA. A 1:30 dilution of the Adaptor Oligo Mix was used in the ligation step. The resulting adapted constructs are amplified by 18 cycles of PCR enriching the DNA fragments with adapters flanking each end. The amplified product was quantified using a spectrophotometer at 260 nm (Nanodrop), and then a portion of final sample is size separated on a 6% TBE (Invitrogen) to verify correct target range amplification. The validated DNA library is submitted at a 10 nmol/L concentration for sequencing. All protocols for Illumina library sequence preparation, sequencing, and quality control are provided by Illumina.
Statistics
Significance was calculated by Student's T-tests. Paired T-tests were used for determining difference in gene expression (Figure 4 ) , and unpaired T-tests were used for calculating difference in cell viability ( Figure 5 ). Significance: * = p<0.05, ** = p<0.01, *** = p<0.0001. Each experiment consists of three independent replicates and is presented as the mean ± the standard deviation.
Results
Identification of genes modulated by GC and further modified by PI3K inhibitor treatment
We had previously observed that the combination treatment of glucocorticoids with a sub-lethal concentration of the PI3K inhibitor LY294002 causes synergistic cell death in the MM.1S human myeloma cell line [Grugan et al., 2008] . In addition, we demonstrated that this combination caused a synergistic increase in gene expression of GILZ (glucocorticoid induced leucine zipper), which contributes to glucocorticoid-induced cell death. Based on these observations, we hypothesized that the subset of glucocorticoid-modulated genes that are further modulated by combination with the PI3K inhibitor would enrich for those genes involved in GCinduced cell death. To identify the cell death gene set, we performed a gene expression array with total RNA isolated from MM.1S cells treated either with glucocorticoids, PI3K inhibitor, a combination of GC + PI3K inhibitor or vehicle control (Figure 1 ). The concentration of PI3K inhibitor is based on previouslypublished dose-response in MM.1S cells [Grugan et al., 2008] where induction of GILZ expression is observed, but there is no increased cell death. Similarly, there is no observed cell death in the GCresistant myeloma cell line MM.1RL. We chose to examine gene expression at a time point of 3 h, where GILZ expression is elevated, but well before initiation of cell death, in order to identify early events in cell death initiation. As shown in the heat map of gene expression (Figure 1 A) , we observed a greater number of down-regulated genes in all treatments as opposed to up-regulated genes similar to published data of GC regulation of gene expression at early time points in myeloma cell lines [Chauhan et al., 2002b] . Using the relaxed cut-off of 1.25-fold change, we found 834 genes down-regulated by Dex, 2235 genes down-regulated by inhibition of PI3K, and 3180 genes down-regulated by the combination drug treatment. In contrast, we observed 388 genes up-regulated by Dex, 832 genes up-regulated by PI3K inhibition, and 1407 genes up-regulated by the combination drug treatment (Figure 1 B) . While genes that are upregulated by combination treatment may be involved in the induction of cell death, we chose to focus on those genes that are down-regulated by combination treatment, due to current therapeutic approaches that favor inhibition of over-expressed proteins through application of small molecule inhibitors. Interestingly, many of the combined treatment down-regulated genes -those genes down-regulated by GC treatment and further down-regulated by combined GC and PI3K inhibition -are known to be involved in cell cycle progression, transcription, translation, 
Clinical relevance of drug-induced downregulated genes is supported by myeloma patient gene expression pattern
To assess the identified gene sets for potential clinical relevance, we used a publicly-available gene expression data set (GSE6691), and we compared the gene expression from the normal B lymphocytes (8 samples) and normal plasma cells (5 samples) to gene expression in myeloma patients (12 samples) [Gutierrez et al., 2007] . The myeloma patients were newly-diagnosed and untreated. Here, we found an almost equivalent number of deregulated genes expressed in MM patients; namely, 2850 genes were down-regulated and 2895 genes were up-regulated compared to control cells. Not surprisingly, when GSEA was performed on these gene sets, we found enrichment for B cell and immune signaling pathways, as well as enrichment of apoptosis, cell death, cancer biology and cell metabolism pathways (GSEA, q<0.05) (Figure 3 A and B, and see Supplementary Material). Using bioinformatics platforms, we next integrated the MM patient gene expression profile (GEP) with our myeloma cell line combination treatment GEP. We identified a gene set that is upregulated in myeloma patients and down-regulated by our combination drug treatment in MM.1S myeloma cell line ( Figure 3C ), with the hypothesis that this gene set would be amenable to therapeutic targeting in myeloma patients through small molecule inhibitors. We observed 266 genes to be downregulated by the combination treatment. Of those, 97 genes were up-regulated in the myeloma patient GEP data set. In contrast, of 125 genes up-regulated by combination treatment in myeloma cells, 25 of those genes were down-regulated in the MM GEP.
Identification of direct GR gene targets in the MM.1S genome
To refine the list of potential therapeutic targets, we sought to identify combination treatment-regulated genes potentially under the direct transcriptional control of GR. These candidate direct targets are likely to be nodes of control that impact a network of downstream targets to induce cell death, making them therapeutically-relevant targets. To identify the potential direct targets of GR transcriptional (p<10-432) . To pair the GR binding sites to genes, the binding information was overlaid on the UCSC genome browser, and genes with binding were defined as containing a GR binding site at a distance up to 100kB from the transcriptional start site of each gene. This parameter was used because GR has been described to bind to enhancer regions up to 100kB from the transcription start site . While this cut-off may not identify all GC-regulated genes with GR binding sites, it provides a starting point for analysis and identification of potential candidate genes. Using this data, we were able to select those Dex/LY294002 combination treatment-regulated genes that may be direct transcriptional targets of GR and clinicallyrelevant based on GEP of MM patients. We identified 57 genes down-regulated by GC/PI3K inhibitor treatment that are candidates for GR binding in myeloma ( Table 1 ) and 22 that are up-regulated (Table 2) . Therefore, we have identified the potential direct GR transcriptional targets whose repression correlates with Dex-induced myeloma cell death. Of note, motifs enriched at the GR peaks within 100kB from the genes presented in Table 1 and Table 2 include GR (p<10E-17 for Table 1, p<10E-22 for  Table 2 ) and Fli1/ETS (p<10E-14 for Table 1, p<10E-9 for Table 2 ) motifs.
GR modulates anti-apoptotic and nucleotide metabolism pathways
We hypothesize that these candidate transcriptional targets of GR may be acting as nodes to regulate the downstream events of glucocorticoid-induced cell death. We performed GSEA of GR-regulated genes using the set of genes that are down-regulated by combination treatment and have potential GR binding sites to gain a global understanding of pathways potentially involved in cell death that may be directly modulated by glucocorticoids (Figure 4 A) . Gene sets involving the cell cycle, nucleotide metabolism, transcription and major growth-promoting signaling pathways were enriched for down-regulated genes, indicating these mechanisms are repressed by GR actions following glucocorticoid treatment.
From our list of candidate genes (Table 1) , we chose two genes to validate their role in glucocorticoidinduced cell death, as proof of principle for our identification approach. We chose two distinct genes within down-regulated pathways identified in the GSEA analysis, BCL2L1 and RRM2, to validate as GR-targeted, death-inducing genes. B-cell lymphomaextra-large (BCL2L1/BCL-XL) is a member of the BCL2 family of anti-apoptotic proteins, and inhibitors of the BCL2 family and inhibition of this protein specifically has been demonstrated to cause death in myeloma cell lines [Chauhan et al., 2007] . In our GEP of combination drug treatment, BLC2L1 was one of the most repressed genes, with a 0.20-fold change of expression compared to the control. Additionally, BCL2L1 expression is increased 1.78-fold in myeloma patients compared to healthy controls (Table 1) . Strong GR binding was identified within 10kB of the promoter (see Supplementary Material). To confirm regulation of BCL-XL by combined Dex and LY294002 treatment, we measured mRNA by qRT-PCR and protein expression by immunoblot (Figure 4 B and D). We observed a decrease in both mRNA and protein expression following glucocorticoid treatment that was further decreased by the addition of PI3K inhibitor LY294002.The validation of BCL2L1 as a primary target for glucocorticoid regulation involved in glucocorticoid-induced cell death validates our target identification process.
Next, we tested our identification process with a gene in a complementary pathway that had not yet been identified as a primary GR target. Ribonucleotide reductase M2 (RRM2) catalyzes the formation of deoxyribonucleotides from ribonucleotides, which is essential for nucleic acid production for DNA replication and repair [Zhou et al., 2013] . Small molecule inhibitors are in development targeting RRM2 as a potential therapeutic target in breast cancer [Shah et al., 2014] . In our screening, we observed RRM2 expression is significantly overexpressed in MM patients (4.47-fold change, Table 1 ); RRM2 expression was reduced upon combination treatment compared to the control in our gene expression array (0.50-fold change), and contains a potential GR binding site within 100kB of the transcription start site (see Supplementary Material). The potential GR binding site for RRM2 is in the promoter region for the KLF11 gene. None of our treatments resulted in a change in KLF11 expression (data not shown); therefore, we believe it is reasonable to assign this GR binding site to regulation of RRM2. The reduction of RRM2 mRNA and protein levels following combined Dex and LY294002 treatment was confirmed by qRT-PCR and immunoblot ( Figure 4 C and D) . BCL-XL and RRM2 are key players in distinct pathways essential for cell 
Discussion
Although glucocorticoids can be an effective therapeutic for the treatment of myeloma, efficacy of this approach is limited by loss of GR expression. Therefore, delineation of the GR targets which direct myeloma cell death and therapeutic intervention at that level may obviate the need for an active GR in advanced myeloma. Here, we have taken a systematic approach to the genomic dissection of GRinduced cell death specific to myeloma through the integration of multiple data sets. To focus on the GR actions that induce myeloma cell death, we co-treated with a PI3K inhibitor which we have previously shown to induce synergistic cell death in myeloma cells. Utilizing publicly-available data sets from myeloma patients, we assessed clinical relevance of our myeloma cell line GEP and finally examined genomic GR binding sites in myeloma cells to identify potential primary GR targets that could be clinically-relevant for treatment of myeloma. This global genomic dissection of gene expression changes following treatment with glucocorticoids in combination with PI3K inhibitors has identified druggable pathways that can be exploited for therapeutic advantage in advanced myeloma.
Microarray analyses of glucocorticoid-induced changes in gene expression have been performed on a number of tissues and cell lines in an attempt to identify key genes regulated for development of new therapeutic approaches. We observed approximately twice as many down-regulated genes as up-regulated at the time point of 3 h of incubation. Chauhan et al. [Chauhan et al., 2002a ] also observed a preponderance of GC-induced down-regulated genes in myeloma cell lines at 3 h of incubation. In mice injected with synthetic GCs 3 h prior to sacrifice, examination of GC-regulated genes in the liver indicate 70% of the genes were down-regulated compared to 30% up-regulated [Phuc Le et al., 2005] . In contrast, in breast cells [Wu et al., 2004] or in human T-cell lymphoma cell lines or mouse thymus [Wang et al., 2003] , the majority of GC-regulated genes were up-regulated rather than down-regulated. Because glucocorticoids impact many tissue types and regulate a wide spectrum of biological responses, it is not unexpected that there should be differences in gene expression between tissue types.
Inhibition of BCL2L1 has been previously observed to cause cell death in myeloma, and therapeutics are in development to target this protein in myeloma [Chauhan et al., 2007] . Our identification of BCL2L1 as a GR target in myeloma and subsequent confirmation of its participation in GC-induced cell death validates our genomics approach. In addition to myeloma, overexpression of BCL-XL has been shown to play a role in additional cancers. For example, BCL-XL may be involved in resistance to common breast cancer therapeutics, such as 5-fluoruracil and doxorubicin [Wang et al., 2015] . Another study demonstrated that reduction of BCL-XL in colorectal cancer improves KRAS-dependent apoptosis resistance [Okamoto et al., 2015] . Inhibition or reduction of BCL-XL expression also induces colorectal cancer cell apoptosis and reduces invasion [Liu et al., 2014; Ye et al., 2015] . Inhibition of BCL-XL in small-cell lung cancer sensitized cells to radiation therapy [Loriot et al., 2014] . Overall, overexpression of BCL-XL is critical to cell survival in various cancer types. Our study confirms these findings and provides further evidence for the use of BCL-XL inhibitors to treat myeloma and other cancers.
Our identification of RRM2 as a GR target and possible therapeutic target in myeloma is novel. Targeting of RRM2 has not been previously explored in myeloma, and this approach could complement current therapeutics. RRM2 is overexpressed in nearly all cancer types that are publicly-available in the Oncomine database. This includes bladder, brain, breast, cervical, colorectal, esophageal, gastric, head/neck, kidney, liver, lung, ovarian, pancreatic and prostate cancers, as well as lymphoma, melanoma and sarcoma. Recent publications implicate the overexpression of RRM2 with higher grade tumors and poor patient survival. For example, RRM2 may act as a prognostic marker for breast cancer and for tamoxifen resistance [Putluri et al., 2014] . RRM2 may Nuclear Receptor Signaling | www.nrsignaling.org NRS | 2015 | Vol. 13 | doi:10.1621/nrs.13006 | 13 also serve as marker for cervical cancer, with its overexpression correlating with higher grade cancers and predicting poor survival [Su et al., 2014] . Another study implicated RRM2 in promoting angiogenesis in cervical tumors . RRM2 was found to be overexpressed in an array of gastric cancer cell lines and in primary gastric tumor cells and correlated with tumor grade and poor survival time. Knock down of RRM2 with siRNA (similar to our study) in gastric cancer cell lines decreased proliferation, colony formation and invasion and induced apoptosis [Kang et al., 2014] . Another study found RRM2 expression may act as a predictor of prostate cancer recurrence . The current literature validates our findings regarding the importance of RRM2 in cell survival. Furthermore, our study supports the growing body of evidence that RRM2 may be an important biomarker and target in cancers.
In summary, we have developed a biology-guided approach to screening for clinically-relevant GR targets and used this approach to identify 57 candidate genes as potential direct targets of GC actions which are over-expressed in myeloma patients and inhibited by combined treatment with GCs and inhibition of PI3K. As proof of principle for this screening process, we have validated two of the targets as being required for myeloma cell survival and whose inhibition sensitizes cells to GC-induced cell death. Overall, our results identify nearly 400 candidate genes under the transcriptional control of GR, the majority being down-regulated upon Dex treatment. We confirmed two candidate transcriptional targets of GR, namely BCL-XL and RRM2, that are up-regulated in MM patients, are required for cell survival, and inhibition of either protein causes death in myeloma cells sensitive and resistant to Dex, which validated our screening pipeline. Our data suggest targeting these proteins as mono-therapies or in combination may provide novel therapeutic approaches for multiple myeloma and provide the means to identify additional GR transcriptional targets whose inhibition contributes to Dex-induced cell death. Future studies will focus on investigating the therapeutic potential of those genes identified in this screening process.
